MedTrace Logo

A Pilot Biomarker Study Assessing Alpha-synuclein Aggregates Across Biofluid Reservoirs in Patients With Synucleinopathies

NCT04020198 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 8

Last updated 2025-04-06

No results posted yet for this study

Summary

This will be an observational study looking at clinical and biomarker characteristics in patients with Parkinson's Disease (PD), Multiple System Atrophy (MSA), Rapid Eye Movement Sleep Behavior Disorder (RBD), Normal Pressure Hydrocephalus and matched controls. Saliva, plasma, serum, urine, and cerebrospinal fluid (CSF) samples will be collected from participants.

Conditions

  • Parkinson Disease
  • Multiple System Atrophy
  • Rapid Eye Movement Sleep Behavior Disorder
  • Normal Pressure Hydrocephalus

Interventions

OTHER

Biomarker assay

Biomarker assay will be used to quantify levels of misfolded alpha-synuclein aggregates in biofluid samples from patients with Parkinson's disease, multiple system atrophy, rapid eye movement sleep behavior disorder, normal pressure hydrocephalus and controls.

Sponsors & Collaborators

Principal Investigators

  • Carine W. Maurer, MD, PhD · Stony Brook University Medical Center

Eligibility

Min Age
50 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-01-15
Primary Completion
2022-10-19
Completion
2022-10-19

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04020198 on ClinicalTrials.gov